Byerly et al. found that inhibiting PKCθ kinase activity in TNBC cells enhanced the chemotherapy sensitivity by modulating the expression of Bim, a pro-apoptotic BCL2-family protein [60] and PKCθ knockdown reduced tumor growth of TNBC cells [61]. The gene discussed is PRRT2; the disease is neoplasm.